The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells

Isabelle Cadron*, Toon Van Gorp, Attila Mihalyi, Catherina Luyten, Katrien Drijkoningen, Frederic Amant, Karin Leunen, Ignace Vergote

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


In this study the modulatory effect of the proteinase kinase C beta (PKC beta) selective inhibitor enzastaurin on CA125 expression and shedding in ovarian cancer cells (OVCAR-3 cells) was investigated. MATERIAL ANDMETHODS: OVCAR-3 cells were cultured in vitro and treated with increasing concentrations of carboplatin (2-1000 microM), paclitaxel (0.2-100 nM) or enzastaurin (1-100 microM) single agent. Growth inhibitory effects were evaluated by MTS and luminescence assay. CA 125 was determined in supernatans and in cell lysate using an electrochemo-iluminescence immunoassay.Cell growth of OVCAR-3 cells was inhibited by single agent carboplatin, paclitaxel or enzastaurin in a dose dependent manner. Carboplatin caused a transient increase of CA125 in supernatans followed by a gradual decrease of CA125. Treatment with increasing doses of paclitaxel or enzastaurin caused an increase of CA125 shedding in culture medium but also the membrane bound fraction of CA125 was increased.These results suggest that enzastaurin, as paclitaxel, has a direct stimulatory effect on CA 125 synthesis and shedding in vitro.
Original languageEnglish
Pages (from-to)64-68
JournalGynecologic Oncology
Issue number1
Publication statusPublished - Jul 2010


  • Ovarian cancer
  • Enzastaurin
  • Biomarker
  • CA 125
  • OVCAR-3 cells

Cite this